Sentences with phrase «studying immune checkpoints»

To optimize the patient response to cancer vaccination requires studying immune checkpoints like CTLA - 4 and the mechanisms of tumor immune evasion.

In my experience, this marks both the first clinical trial of an approved drug with an effect on survival in advanced melanoma in the adjuvant setting, and, in this same setting, the first to study an immune checkpoint inhibitor in the adjuvant setting.

R&D Systems offers a wide range of reagents and kits designed to study the immune checkpoint, including blocking antibodies, proteins, assays, and more.

Not exact matches

One recent tally found more than 1100 studies combining a popular new class called checkpoint inhibitor drugs, which unleash suppressed immune cells, with other treatments.

Patients with metastatic melanoma who were treated with ipilimumab, an immune checkpoint blocker, survived 50 percent longer — a median 17.5 months vs. 12.7 months — if they simultaneously received an immune stimulant, according to a study led by Dana - Farber Cancer Institute scientists.

Patients in the study were treated with immune checkpoint inhibitors that block the activation of PD1, a protein on immune system T cells that halts immune response.

Their study of fecal samples from 105 patients treated with immune checkpoint blockade indicates that certain characteristics of patients» microbiomes correlate with slower disease progression while other qualities are associated with rapid worsening of the disease.

Results of an initial study of tumors from patients with lung cancer or head and neck cancer suggest that the widespread acquired resistance to immunotherapy drugs known as checkpoint inhibitors may be due to the elimination of certain genetic mutations needed to enable the immune system to recognize and attack malignant cells.

«TCF - 1 is the focus of many immunology and oncology studies, especially those dealing with checkpoint inhibitors and sick immune cells.

Commenting on the two studies, Baas says that finding a good treatment for mesothelioma has been a challenge for many years and has so far led to many disappointments, so there is a need for investigation into new pathways such as the use of immune checkpoint inhibitors that target the PD - 1 / PD - L1 pathway.

The study compared four PD - L1 IHC diagnostic assays developed in conjunction with four PD - 1 / PD - L1 immune checkpoint inhibitors, which are used in NSCLC clinical trials.

Vladimir Vigdorovich, Ph.D., a CRI postdoctoral fellow at Albert Einstein College of Medicine, studies B7x, which is an immune checkpoint molecule that can inhibit T cell function.

Bottom Line: Bacterial load was significantly higher in pancreatic tumor samples from patients with pancreatic ductal adenocarcinoma compared with pancreatic tissue from normal individuals, and in studies using mice, eliminating certain «bad» bacteria slowed the growth of pancreatic cancer, reversed immune suppression, and upregulated the immune checkpoint protein PD1.

The study highlights an opportunity to combine this form of therapy with cancer immunotherapy drugs such as checkpoint inhibitors, which unleash the immune system's full cancer - fighting power, the researchers say.

In the next year, members of the Dream Team will continue to study the tumor microenvironment before and after checkpoint blockade, to develop algorithms to identify and predict the best antigens on cancer cells that can be used for cancer immunotherapies, to analyze tumor tissues and blood for biomarkers that will help in selecting patients who will benefit, and identifying the best approaches to increase the strength of immune cells for adoptive cell therapy.

Led by Leena Gandhi, MD, PhD, associate professor of medicine and director of thoracic medical oncology, researchers from the KEYNOTE - 021 study demonstrated for the first time that combining an immune checkpoint inhibitor — in this case, pembrolizumab — with a platinum - doublet chemotherapy regimen might be more effective than chemotherapy alone as first - line treatment for advanced, non-squamous NSCLC.

To combat the nation's third deadliest cancer, the phase 1b / 2 open - label study will explore the combination of standard chemotherapy and two immunotherapy agents: an anti-PD-1 checkpoint inhibitor and a novel antibody targeting CD40, a protein that when activated can drive the immune system to attack tumors.

The combination of the attenuated oncolytic virus talimogene laherparepvec (T - VEC) and the immune checkpoint inhibitor pembrolizumab shows activity and is well tolerated by advanced melanoma patients, according to a new study presented at the Society for Melanoma Research 2015 International Congress, held November 18 — 21 in San Francisco.